CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency

Clinical Immunology : the Official Journal of the Clinical Immunology Society
Timothy J PowellR W Dutton

Abstract

The activation, localization, phenotypic changes, and function of CFSE-labeled naive influenza-specific CD8(+) and CD4(+) T cells following influenza infection were examined. Response of adoptively transferred CD8(+) T cells was seen earliest in draining lymph node. Highly activated cells were found later in the lung, airways, and spleen, were cytolytic, and expressed IFN-gamma upon restimulation. Similar amounts of division at early time points, but higher numbers of CD8(+) T cells, were detected at 9 and 30 days postinfection after cotransfer of CD4(+) and CD8(+) T cells followed by infection. Transfer of much smaller numbers of CD4(+) and CD8(+) T cells led to more extensive expansion but the same difference in final number between the two cell types. These studies demonstrate how CD8(+) and CD4(+) T cells respond to influenza at early time points postinfection and the differential kinetics of antigen-specific CD4(+) and CD8(+) T cells.

Citations

Jan 24, 2008·Immunologic Research·K Kai McKinstrySusan L Swain
May 18, 2005·The Journal of Experimental Medicine·Reinhard ObstChristophe Benoist
Jan 31, 2007·The Journal of Experimental Medicine·Mandy L FordChristian P Larsen
Aug 3, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Arunakumar GangaplaraJay Reddy
Jul 20, 2010·Immunological Reviews·K Kai McKinstrySusan L Swain
Mar 5, 2005·Trends in Immunology·Linda M BradleySusan L Swain
Jan 3, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Timothy J PowellRichard W Dutton
Aug 10, 2010·The Australian Journal of Rural Health·Rachel ThamKaren Riley
Sep 15, 2005·Journal of Experimental Zoology. Part A, Comparative Experimental Biology·Eric V YangRoy A Tassava
Sep 7, 2005·European Journal of Immunology·Marie J EstcourtTomás Hanke
Mar 1, 2006·Expert Review of Clinical Immunology·David J TophamMartin Richter
Jan 28, 2014·The Australian Journal of Rural Health·Jane E TomnayChristopher K Fairley
Dec 24, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·E Bridie ClemensStephen J Turner
Oct 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Susan L Swain
Jan 5, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Timothy J PowellRichard W Dutton
Mar 7, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hiromasa HamadaRichard W Dutton
Dec 1, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hiromasa HamadaRichard W Dutton
Jan 12, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul G ThomasPeter C Doherty
Sep 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cris KamperschroerSusan L Swain
Oct 4, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jojanneke HeidemaGrada M van Bleek
Oct 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cris KamperschroerSusan L Swain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.